Skip to main content
NIH funding notice RFA-NS-18-042

Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R21 Clinical Trial Not Allowed)

Closed on November 12, 2019.

Posted
September 19, 2018
Close date
November 12, 2019
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $619,850 in first-year total cost, median $309,925.

Most frequent study sections

  1. Special Emphasis Panel[ZRG1 IFCN-N (55)]2

Most frequent institutions

  1. UNIVERSITY OF MINNESOTA1
  2. UNIVERSITY OF SOUTH FLORIDA1
Competing awards under RFA-NS-18-042 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2020Vagal nociceptive pathway mediating pain from the esophagus1R21DK124894-01TAYLOR-CLARK, THOMAS EDWARDUNIVERSITY OF SOUTH FLORIDA, FL$224,250ZRG1
2019Targeting the Vgf signaling system for new chronic pain treatments1R21NS113335-01VULCHANOVA, LYUDMILA HUNIVERSITY OF MINNESOTA, MN$395,600ZRG1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.